These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 2553933

  • 21. Receptor pharmacology.
    Young A.
    Adv Pharmacol; 2005; 52():47-65. PubMed ID: 16492540
    [Abstract] [Full Text] [Related]

  • 22. Characterization of calcitonin gene-related peptide (CGRP) receptors in guinea pig basilar artery.
    Jansen I.
    Neuropeptides; 1992 Feb; 21(2):73-9. PubMed ID: 1313553
    [Abstract] [Full Text] [Related]

  • 23. Human alpha-calcitonin gene-related peptide-(8-37) as an antagonist of exogenous and endogenous calcitonin gene-related peptide.
    Maggi CA, Chiba T, Giuliani S.
    Eur J Pharmacol; 1991 Jan 03; 192(1):85-8. PubMed ID: 2040366
    [Abstract] [Full Text] [Related]

  • 24. Structure-activity studies on position 14 of human alpha-calcitonin gene-related peptide.
    Li J, Matsuura JE, Waugh DJ, Adrian TE, Abel PW, Manning MC, Smith DD.
    J Med Chem; 1997 Sep 12; 40(19):3071-6. PubMed ID: 9301670
    [Abstract] [Full Text] [Related]

  • 25. Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2, 7)]hCGRP-preferring receptor.
    Wu D, Eberlein W, Rudolf K, Engel W, Hallermayer G, Doods H.
    Eur J Pharmacol; 2000 Jul 21; 400(2-3):313-9. PubMed ID: 10988349
    [Abstract] [Full Text] [Related]

  • 26. Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins.
    Kuwasako K, Cao YN, Nagoshi Y, Tsuruda T, Kitamura K, Eto T.
    Mol Pharmacol; 2004 Jan 21; 65(1):207-13. PubMed ID: 14722252
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. In vivo modulation of sigma receptor sites by calcitonin gene-related peptide in the mouse and rat hippocampal formation: radioligand binding and electrophysiological studies.
    Bouchard P, Monnet F, Bergeron R, Roman F, Junien JL, de Montigny C, Debonnel G, Quirion R.
    Eur J Neurosci; 1995 Sep 01; 7(9):1952-62. PubMed ID: 8528471
    [Abstract] [Full Text] [Related]

  • 29. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S, Kezar HS, Carter RL, Saini SK, Rice KC, Wells JL, Davis P, Xu H, Dersch CM, Bilsky EJ, Porreca F, Rothman RB.
    J Med Chem; 1999 Sep 09; 42(18):3527-38. PubMed ID: 10479286
    [Abstract] [Full Text] [Related]

  • 30. Characterization and photoaffinity labeling of a calcitonin gene-related peptide receptor solubilized from human cerebellum.
    Stangl D, Born W, Fischer JA.
    Biochemistry; 1991 Sep 03; 30(35):8605-11. PubMed ID: 1653602
    [Abstract] [Full Text] [Related]

  • 31. Solubilization and characterization of a guanine nucleotide-sensitive form of the calcitonin gene-related peptide receptor.
    Chatterjee TK, Moy JA, Cai JJ, Lee HC, Fisher RA.
    Mol Pharmacol; 1993 Feb 03; 43(2):167-75. PubMed ID: 8381507
    [Abstract] [Full Text] [Related]

  • 32. Calcitonin gene-related peptide (hCGRP alpha) binding sites in the nucleus accumbens. Atypical structural requirements and marked phylogenic differences.
    Dennis T, Fournier A, Guard S, St Pierre S, Quirion R.
    Brain Res; 1991 Jan 18; 539(1):59-66. PubMed ID: 1849780
    [Abstract] [Full Text] [Related]

  • 33. Pharmacological characterization of CGRP1 receptor subtype in the vascular system of the rat: studies with hCGRP fragments and analogs.
    Donoso MV, Fournier A, St-Pierre S, Huidobro-Toro JP.
    Peptides; 1990 Jan 18; 11(5):885-9. PubMed ID: 1704613
    [Abstract] [Full Text] [Related]

  • 34. Neuropeptide receptors in developing and adult rat spinal cord: an in vitro quantitative autoradiography study of calcitonin gene-related peptide, neurokinins, mu-opioid, galanin, somatostatin, neurotensin and vasoactive intestinal polypeptide receptors.
    Kar S, Quirion R.
    J Comp Neurol; 1995 Apr 03; 354(2):253-81. PubMed ID: 7782502
    [Abstract] [Full Text] [Related]

  • 35. Studies on the effects of the N-terminal domain antibodies of calcitonin receptor-like receptor and receptor activity-modifying protein 1 on calcitonin gene-related peptide-induced vasorelaxation in rat uterine artery.
    Chauhan M, Gangula PR, Wimalawansa SJ, Yallampalli C.
    Biol Reprod; 2004 Jun 03; 70(6):1658-63. PubMed ID: 14960487
    [Abstract] [Full Text] [Related]

  • 36. Development of natriuretic peptide analogs selective for the atrial natriuretic factor-R1A receptor subtype.
    Mimeault M, Fournier A, Féthiere J, De Léan A.
    Mol Pharmacol; 1993 May 03; 43(5):775-82. PubMed ID: 8502232
    [Abstract] [Full Text] [Related]

  • 37. Conformational and biological studies of neuropeptide Y analogs containing structural alterations.
    Fournier A, Gagnon D, Quirion R, Cadieux A, Dumont Y, Pheng LH, St-Pierre S.
    Mol Pharmacol; 1994 Jan 03; 45(1):93-101. PubMed ID: 8302286
    [Abstract] [Full Text] [Related]

  • 38. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist.
    Aiyar N, Daines RA, Disa J, Chambers PA, Sauermelch CF, Quiniou M, Khandoudi N, Gout B, Douglas SA, Willette RN.
    J Pharmacol Exp Ther; 2001 Mar 03; 296(3):768-75. PubMed ID: 11181905
    [Abstract] [Full Text] [Related]

  • 39. Regional distribution and regulation of [125I]calcitonin gene-related peptide binding sites in coronary arteries.
    Knock GA, Wharton J, Gaer JA, Yacoub MH, Taylor KM, Polak JM.
    Eur J Pharmacol; 1992 Sep 04; 219(3):415-25. PubMed ID: 1330610
    [Abstract] [Full Text] [Related]

  • 40. Differential effects of guanine nucleotides on [125I]-hCGRP(8-37) binding to porcine lung and human neuroblastoma cell membranes.
    Aiyar N, Disa J, Siemens IR, Nambi P.
    Neuropeptides; 1997 Feb 04; 31(1):99-103. PubMed ID: 9574846
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.